HIV Roundtable: Managing medications after diagnosis
Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.
HIV Roundtable:
Welcome to the first episode of our 3-episode series; HIV Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.
This series discusses several aspects of HIV including clinical management, therapies, vaccines, and multidrug resistance.
In this episode, our panel offers their approaches to care in terms of medications and management when patients are first diagnosed and a discussion around long-acting injectables for HIV management.
Panel:
- MJ Kasten, MD, associate professor of Medicine, consultant, Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Internal Medicine, Mayo Clinic
- Natasha Hoyte, MPH, CPNP-PC, New York-Presbyterian School Based Health Centers
- Aimalohi Ahonkhai, MD, MPH, associate physician, medicine at the Massachusetts General Hospital, associate director of the Bio-behavioral and Community Science Core and director of the Community Engaged Research Program for the Harvard University Center for AIDS Research
- Jessica Castilho, MD, associate professor of Medicine, Division of Infectious Diseases, associate professor, Dept. of Health Policy, Vanderbilt University Medical Center
Current treatments for recurrent bacterial vaginosis leave many patients dissatisfied
February 28th 2025A new study presented at ISSWSH highlights patient dissatisfaction with current treatments for recurrent bacterial vaginosis, emphasizing the need for more effective therapies and improved provider communication.
Read More
Dequalinium chloride found noninferior to metronidazole for BV treatment
May 9th 2024Explore how dequalinium chloride stands as a promising alternative to metronidazole in treating bacterial vaginosis, offering comparable efficacy, safety, and tolerability, as revealed by a recent noninferiority trial.
Read More
